The most telling part of the LBBP-FAVOUR story isn’t that left bundle branch pacing (LBBP) beat right ventricular pacing (RVP) in a composite outcome. Personally, I think it’s that the difference showed up where we’ve long suspected the real problem lies: pacing-induced cardiomyopathy (PICM). When a therapy consistently reduces the downstream damage—even if other “hard” endpoints don’t move much yet—it should change how clinicians think, not just what they prescribe. And what makes this particularly fascinating is how it reframes the argument from “do we improve survival?” to “do we prevent the biology that leads to failure?”
What the trial actually found
LBBP significantly reduced a composite endpoint that included all-cause mortality, heart-failure (HF) hospitalization, and PICM in high pacing burden patients who were at high risk of cardiac dysfunction, compared with RVP. The average follow-up was about 36 months, and the benefit was largely driven by fewer cases of PICM in the LBBP arm. In my opinion, that detail matters because PICM is not a side quest—it’s a plausible mechanistic pathway by which pacing can slowly erode cardiac function over time.
The trial randomized 160 patients across multiple Chinese centers in a 1:1 ratio to LBBP or RVP. The primary composite occurred in 11.6% of the LBBP group versus 33.9% of the RVP group. If you translate that into everyday clinical language, that’s a dramatic relative reduction in a condition that can later translate into HF events.
But here’s the nuance people may overlook: while the composite improved, all-cause mortality and HF hospitalization did not show statistically significant differences between the pacing strategies. Personally, I think this is exactly the kind of “mixed” result that gets overinterpreted by both sides—sometimes by those who dismiss the findings, and sometimes by those who overpromise benefits that the data don’t yet prove.
Why PICM prevention is the real headline
PICM occurred in 6.5% with LBBP versus 18.2% with RVP. From my perspective, that pattern is the clearest signal in the entire report because it directly addresses the harmful remodeling that pacing can trigger. What many people don’t realize is that HF hospitalization and mortality often require longer time horizons, larger sample sizes, or different event rates to show differences—especially in studies powered around composites rather than each component independently.
This raises a deeper question: should we value “near-term biological protection” even when “late clinical endpoints” don’t yet separate? Personally, I think we often underweight surrogate pathways when we’re hungry for dramatic outcomes. But in cardiology, we’ve learned the hard way that remodeling and functional decline are the quiet architects of future events. If LBBP preserves the myocardium early, it may take time before that translates into fewer admissions or deaths—and the trial may simply not have been long enough (or large enough) to demonstrate that downstream effect.
What makes this especially interesting is the psychology of clinical interpretation. When mortality doesn’t differ, skeptics often treat the whole study as a disappointment, as if prevention is somehow less important than outcome. Meanwhile, enthusiasts may jump ahead as though every component must improve before we can act. The truth is more mature: prevention can be a meaningful endpoint in itself, particularly when it is biologically coherent and supported by changes in cardiac structure and function.
Evidence of preserved structure and function
Beyond event rates, investigators reported “superior improvements” with LBBP over the follow-up period in measures tied to cardiac mechanics—left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, and left ventricular end-systolic diameter. In my opinion, this reinforces that the reduction in PICM wasn’t just statistical luck; it reflects a consistent directional effect on remodeling.
They also observed more favorable changes in NYHA functional class with LBBP. This is one of those outcomes that can feel “soft,” but for patients it’s anything but. Functional class improvements often correlate with symptoms, exercise tolerance, and quality of life—things clinicians and patients experience every day. From my perspective, when you see both imaging/physiology improvements and patient-centered functional gains, you’re looking at a therapy that plausibly changes the disease trajectory rather than merely shifting event counting.
A detail that I find especially interesting is how these improvements align with what we’d expect from a pacing strategy that better preserves electrical and mechanical synchrony compared with conventional right-sided pacing. Even if the trial doesn’t fully settle every question about long-term mortality, it strengthens the argument that LBBP is doing what it claims at the level of cardiac behavior.
The patient selection question
The trial enrolled high pacing burden patients at high risk of cardiac dysfunction. Personally, I think that’s not just a demographic detail—it’s the crux. If a therapy’s advantage is mechanistic, then the benefit should concentrate where the mechanism has room to cause harm. In other words, the sickest “pacing-susceptible” patients are the ones most likely to show differentiation.
This is where clinical reality gets tricky. Many clinicians will wonder: “Does this mean everyone should get LBBP?” My answer is: not necessarily. What this suggests is that the right pacing strategy may be less about universal switching and more about risk stratification—identifying who is most vulnerable to dyssynchrony and pacing-mediated remodeling.
If you take a step back and think about it, the trial nudges us toward a more personalized device strategy. Historically, many pacing decisions were driven by technical availability, operator preference, and broad guideline recommendations. But as evidence grows, the standard of care should move toward matching pacing modality to the individual’s risk of pacing-induced dysfunction.
Why HF hospitalization and mortality didn’t significantly differ
One thing that immediately stands out is the gap between dramatic PICM reduction and non-significant differences in mortality or HF hospitalization. Personally, I don’t see that as a contradiction; I see it as a timeline mismatch. HF events and deaths typically lag behind structural/functional injury, and they can be influenced by many factors beyond pacing modality—medication optimization, comorbidities, follow-up intensity, and competing risks.
Sample size matters too. With 160 patients, even fairly large relative differences in composite components can fail to reach statistical significance for individual endpoints—especially if event rates are lower than expected or if the follow-up duration doesn’t capture enough occurrences. What many people don’t realize is that “no significant difference” doesn’t equal “no effect”; it can also mean “we didn’t observe enough signal yet.”
From my perspective, the more responsible interpretation is: LBBP appears to prevent an important intermediary outcome (PICM) and improve cardiac metrics, and that sets up a plausible expectation for fewer future HF events. The trial simply may not have had the power and time to prove that chain all the way to mortality.
Where this could go next
The authors themselves call for larger randomized trials powered for hard outcomes in specific populations. I agree with that framing—because clinicians and health systems will want confirmation on endpoints like mortality and HF hospitalization before making sweeping policy changes.
If I were forecasting the next phase of this field, I’d expect three things to matter most:
- Better patient stratification by pacing burden and baseline risk of ventricular dysfunction
- Longer follow-up to capture whether remodeling prevention translates into fewer HF events
- Standardized device programming and follow-up protocols to reduce “real-world noise” in outcomes
What this really suggests is that we’re moving from “device choice as a technical preference” to “device choice as a disease-modifying decision.” And that’s a cultural shift as much as a clinical one.
The takeaway I’d actually act on
Personally, I think LBBP-FAVOUR should push clinicians to take PICM prevention seriously when they’re dealing with high pacing burden patients at elevated risk. The clearest signal in the dataset is not the composite—it’s the reduction in PICM and the accompanying improvements in ventricular size/function and functional status. Even without statistically significant differences in mortality and HF hospitalization in this study, the directionality is coherent, mechanistically plausible, and clinically meaningful.
If you’re deciding between pacing strategies, the question shouldn’t only be “Will this reduce death?” It should also be “Will this reduce the likelihood that pacing itself starts a remodeling cascade?” From my perspective, that’s where the trial earns its credibility.
Would you like me to rewrite this as a shorter “newsletter-style” version, or keep it as a full editorial piece with a more aggressive point of view?
